jobs

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNexus Gene Lab Corp - Common stock (NQ:BGLC)

1.400 -0.050 (-3.45%)
Streaming Delayed Price Updated: 11:35 AM EDT, Sep 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about BioNexus Gene Lab Corp - Common stock

News headline image
BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit
Meetings in Shanghai and Changzhou link VitaGuard's commercial use in China with BioNexus' Southeast Asian plans and Fidelion's international licensing efforts 
From BioNexus Gene Lab Corp.
Via GlobeNewswire
News headline image
BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development
From BioNexus Gene Lab Corp.
Via GlobeNewswire
News headline image
BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform
From BioNexus Gene Lab Corp.
Via GlobeNewswire
News headline image
BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman
From BioNexus Gene Lab Corp.
Via GlobeNewswire
News headline image
BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN’s Multi-Billion Dollar Market
From BioNexus Gene Lab Corp.
Via GlobeNewswire
News headline image
BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard™
From BioNexus Gene Lab Corp.
Via GlobeNewswire
News headline image
BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization
From BioNexus Gene Lab Corp.
Via GlobeNewswire
News headline image
BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuard™ MRD Platform as Part of Strategic Alliance with Tongshu Gene
From BioNexus Gene Lab Corp.
Via GlobeNewswire
News headline image
BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization
From BioNexus Gene Lab Corp.
Via GlobeNewswire
News headline image
BioNexus Gene Lab Corp. Files $100 Million Shelf Registration and Establishes $20 Million At-the-Market Program to Advance Strategic Growth Opportunities
From BioNexus Gene Lab Corp.
Via GlobeNewswire
News headline image
BioNexus Gene Lab Corp Signs Strategic Partnership Term Sheet with BirchBioMed Inc.
Collaboration Expected to Advance FS2 Topical Platform and Strengthen BGLC’s Biotech Footprint in Asia 
From BioNexus Gene Lab Corp.
Via GlobeNewswire
News headline image
Mag 7 Undercard: REPL, BGLC, TYGO, SGD – More Stocks Inside Heating Up Now!
Via AB Newswire
Topics Economy
News headline image
BioNexus Gene Lab Corp. and Fidelion Diagnostics Announce Landmark Alliance—Touted as a new “DeepSeek Moment” in Precision Oncology
From BioNexus Gene Lab Corp.
Via GlobeNewswire
News headline image
BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness
From BioNexus Gene Lab Corp.
Via GlobeNewswire
News headline image
BioNexus Gene Lab Corp. Files 2024 Annual Report Highlighting Strategic Innovation, Operational Resilience, and Growth Trajectory
From BioNexus Gene Lab Corp.
Via GlobeNewswire
News headline image
BioNexus Gene Lab Corp and ML Tech Partner to Enhance Ethereum-focused Treasury Strategy
From BioNexus Gene Lab Corp.
Via GlobeNewswire
News headline image
BioNexus Gene Lab Corp. Announces Board Approval of Ethereum Treasury Strategy and Release of Strategic Whitepaper
From BioNexus Gene Lab Corp.
Via GlobeNewswire
News headline image
BioNexus Gene Lab Corporation announces entry into Biogas Sector via Teaming Agreement with Protech Builders Sdn. Bhd.
From BioNexus Gene Lab Corp.
Via GlobeNewswire
News headline image
BioNexus Gene Lab Corp. Signs Strategic Outsourcing Agreement with VITARRAY Global Pte. Ltd.
From BioNexus Gene Lab Corp.
Via GlobeNewswire
News headline image
BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions
From BioNexus Gene Lab Corp.
Via GlobeNewswire
News headline image
BioNexus Gene Lab Corp Announces New Business Developments for Subsidiary Chemrex with Investment in High-Quality Color Paste Production
From BioNexus Gene Lab Corp.
Via GlobeNewswire
News headline image
BioNexus Gene Lab Corp. Announces Successful Securities Commission of Malaysia (MyCIF) Co-Investment in Ascension Innovation Sdn Bhd
From BioNexus Gene Lab Corp.
Via GlobeNewswire
News headline image
BioNexus Gene Lab Corp. Completes Strategic RM 1 Million Investment in Ascension Innovation Sdn Bhd
From BioNexus Gene Lab Corp.
Via GlobeNewswire
News headline image
BioNexus Gene Lab Corp. Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare
From BioNexus Gene Lab Corp.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Medicine Hat News Twitter Twitter
Medicine Hat News Facebook Facebook
Medicine Hat News Instagram Instagram
Medicine Hat News YouTube YouTube
Medicine Hat News Tumblr Tumblr

About Us

Contact the Medicine Hat News

922 Allowance Ave SE
Medicine Hat, AB T1A 3G7

Office hours: 8:30 a.m.-4:30 p.m. Monday to Friday, closed Saturday Sunday and statutory holidays.

[P] 403.527.1101
[F] 403-527-0737

Print Advertising: 403.528.5659
National Advertising: 403.528.5766
Online Advertising: 403.528.5698
Classifieds: 403.526.7653

© 1996-2024 The Medicine Hat News